Login / Signup

Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study.

Satoshi YukiKentaro YamazakiYu SunakawaHiroya TaniguchiHideaki BandoManabu ShiozawaTomohiro NishinaHisateru YasuiYoshinori KagawaNaoki TakahashiTadamichi DendaTaito EsakiHiasto KawakamiHironaga SatakeAtsuo TakashimaNobuhisa MatsuhashiTakeshi KatoChiharu AsanoYukiko AbeShogo NomuraTakayuki Yoshino
Published in: Cancer medicine (2023)
Pretreatment plasma IL-8 and sVCAM-1 levels could be predictive biomarkers to distinguish BEV and anti-EGFR mAbs when combined with chemotherapy in the 1L treatment of RAS wild-type mCRC. Several plasma angiogenesis factors showed significant change at progression in 1L chemotherapy plus biologics for RAS wild-type mCRC, which are potential biomarkers for selecting an optimal angiogenesis inhibitor in second-line treatment.
Keyphrases
  • wild type
  • endothelial cells
  • vascular endothelial growth factor
  • locally advanced
  • wound healing
  • squamous cell carcinoma
  • epidermal growth factor receptor